PROLEUKIN

Aldesleukin 22,000,000IU, Lyophilisate for solution for injection

Marijuana

· Severity: Moderate

· Notes for Consumers: The effects of marijuana may be increased and side effects may get worse if it is combined with this medicine. Do not drive or operate machinery until you know how this combination will affect you. Contact your health care provider right away if you notice slurred speech, confusion, severe drowsiness, increased heart rate, or any other new or unusual side effects.

· Notes for Professionals: The incidence of marijuana associated adverse effects may change following coadministration with aldesleukin, IL-2. Aldesleukin is an inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of marijuana's most psychoactive compound, delta-9-tetrahydrocannabinol (Delta-9-THC). When given concurrently with aldesleukin, the amount of Delta-9-THC converted to the active metabolite 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) may be reduced. These changes in Delta-9-THC and 11-OH-THC plasma concentrations may result in an altered marijuana adverse event profile.

Aldesleukin 22,000,000IU, Lyophilisate for solution for injection

Alcohol

· Severity: Moderate

· Notes for Consumers: Talk to your doctor or healthcare professional before drinking alcoholic beverages during Aldesleukin therapy. Aldesleukin can cause liver toxicity. Alcohol can increase the risk of liver toxicity.

· Notes for Professionals: Hepatic function is impaired during therapy with aldesleukin. Concurrent administration of alcohol can add to the hepatic impairment produced by aldesleukin.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.